Clinical Trials Logo

Leiomyoma clinical trials

View clinical trials related to Leiomyoma.

Filter by:

NCT ID: NCT01553123 Withdrawn - Leiomyomas Clinical Trials

Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma

Start date: April 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether ulipristal acetate is effective in the treatment of females with anemia associated with uterine leiomyomas. The safety of this product will also be evaluated.

NCT ID: NCT01328067 Withdrawn - Bleeding Clinical Trials

Study to Evaluate the Safety and Effectiveness of MRgFUS Compared With Myomectomy for the Treatment of Uterine Fibroids

Start date: June 2011
Phase: N/A
Study type: Interventional

The objective of this trial is to evaluate the safety and efficacy of ExAblate for the treatment of uterine fibroids. Women, seeking treatment for symptomatic uterine leiomyomata will be eligible for the study.Women who agree to participate will sign an informed consent and will be randomized to ExAblate treatment or myomectomy. All patients will be followed through the 36 month visit. Follow-up visits/telephone calls will be completed at 1 week, 2 weeks, 6 weeks, 3 months, 6, 12, 18, 24 and 36 months post treatment. Patients will be evaluated by assessing their overall physical and mental health as well as for device/procedure related adverse events.

NCT ID: NCT00945360 Withdrawn - Clinical trials for Symptomatic or Large Uterine Fibroids

Aromatase Inhibitors for Treatment of Uterine Leiomyomas

Start date: March 2011
Phase: Phase 1
Study type: Interventional

Fibroids are benign tumors that might results in bleeding. Surgery is their definitive treatment. Some medical therapies have been tried for women who wish to preserve their uterus. Recent reports have demonstrated a role for a new category of drugs called aromatase inhibitor (such as Femara) in the treatment of fibroids. This study is conducted to assess the effect of Femara (letrozole) on the size of fibroids in women around menopause.

NCT ID: NCT00874302 Withdrawn - Uterine Fibroids Clinical Trials

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

Start date: n/a
Phase: Phase 3
Study type: Interventional

Subjects with symptomatic uterine fibroids will be enrolled and will receive daily oral study medication for 4 months. This will be followed by a 6 month off-drug interval until there is a return of significant symptomatology. If they experience symptoms of a certain severity, the subject will enter a second 4 month treatment cycle and then a follow-up period.

NCT ID: NCT00827645 Withdrawn - Incontinence Clinical Trials

Uterine Artery Embolization and Pelvic Floor Symptoms

Start date: January 1, 2009
Phase:
Study type: Observational

The objective of this study is to determine whether women who are already receiving treatment for their fibroids (ie. UAE) demonstrate improvement in urinary symptoms and sexual dysfunction as well.

NCT ID: NCT00768742 Withdrawn - Uterine Fibroids Clinical Trials

Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study

FAST
Start date: September 2008
Phase: N/A
Study type: Interventional

The primary objective of this study is to test the hypothesis that a minimum 75% volume radiofrequency ablation of fibroids associated with menorrhagia results in reduction of menstrual bleeding.

NCT ID: NCT00180739 Withdrawn - Pregnancy Clinical Trials

Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future

Start date: April 2004
Phase: Phase 4
Study type: Interventional

The study objective is to develop data for the safety of pregnancies after thermal ablation of uterine fibroids by MR guided Focused Ultrasound using the Ex Ablate 2000 system.